Blood test clue for cancer treatment success?

NCT ID NCT07363811

Recruiting now Knowledge-focused Sponsor: Necmettin Erbakan University Source: ClinicalTrials.gov ↗

Summary

This study aims to find out if the level of a specific type of white blood cell, called a Large Granular Lymphocyte (LGL), can help predict how well patients with advanced non-small cell lung cancer will respond to the immunotherapy drug nivolumab. Researchers will measure LGLs in the blood of 50 participants at the start of treatment and again after three months. They will then check if these levels are linked to how the cancer shrinks and how long patients live.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology
RECRUITING

Konya, Meram, 42090, Turkey (Türkiye)

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER